

August 8, 2025

Company name: Amvis Holdings, Inc.
Name of representative: Keiichi Shibahara, Representative Director and CEO
Securities code: 7071; Tokyo Stock Exchange Prime
Inquiries: Shingo Yamaguchi, Director

Notice on Receipt of the Investigation Report from the Special Investigation Committee

As announced in the release titled “Establishment of a Special Investigation Committee” dated March 27, 2025, established a Special Investigation Committee comprised of independent external experts, with the objective of conducting an objective, comprehensive, and in-depth investigation into the factual circumstances and background surrounding the reports alleging improper billing of medical fees.

We hereby announce that we have received the investigation report from the Special Investigation Committee as of today, as outlined below.

We sincerely apologize once again to our residents and their families, investors and shareholders, business partners, and all other stakeholders for the great concern and inconvenience caused.

1. Findings of the Special Investigation Committee

Please refer to the disclosure materials provided in Japanese for the details of the Special Investigation Committee's findings.

Kindly note that certain portions of the investigation report have been redacted to protect personal privacy and the confidential information of business partners.

2. Investigation Methodology and Summary of Findings

- (1) The Special Investigation Committee was established, led primarily by an external law firm, comprising two attorneys, one certified public accountant, and 16 assistant attorneys and other personnel. The Company fully cooperated with the investigation.
- (2) The investigation conducted by the Special Investigation Committee was carried out over a period exceeding four months, from March 27 to August 4. The scope of the investigation encompassed the minutes of meetings of the Board of Directors, Executive Management Committee, and Audit & Supervisory Board; all visit records during the investigation period stored in the current home-visit nursing record system; emails, Teams chats, attachments; and records related to insurance reimbursements. Furthermore, a comprehensive and multifaceted investigation and verification process was undertaken through interviews and surveys involving a total of 247 individuals, including company personnel and former officials of the Ministry of Health, Labor and Welfare—such as a former bureau chief—amounting to 253 interview instances in total. An information provision contact point was also established to facilitate the collection of relevant information.
- (3) As a result, the Committee determined that there was no evidence of systematic misconduct or fraudulent billing as alleged in some media reports.

3. Impact on Financial Results for the Six Months Ending March 31, 2025

The financial impact identified through this investigation is minor, amounting to approximately ¥63 million (around 0.05% of total revenue during the investigation period). Accordingly, the Company does not plan to revise past securities reports and intends to record the full amount as a provision in the second quarter results for the fiscal year ending September 2025.

This provision is based on the Committee's assessment of visit nursing records that serve as the basis for revenue, according to certain criteria established by the Committee. These records were deemed to lack sufficient documentation to demonstrate the actual nursing practices, but were not determined to lack substantive nursing activity.

Therefore, even if any misbilling were to be officially recognized, the Company believes the actual amount would be even smaller. Please note that the provision amount is not indicative of the actual refund amount.

4. Company's View on the Investigation Results

- (1) The Company recognizes that the Committee acknowledged the substance and integrity of our medical practices based on the fact that the majority of residents at our "Ishinkan" facilities are in the terminal stage of incurable illnesses such as cancer, and that we have sincerely strived to improve medical quality and care as a pioneer in hospice services.
- (2) With regard to the impact amount mentioned above, we understand that the majority of cases in which our actual nursing practices were not recognized stemmed from formal errors such as incorrect data entry and insufficient documentation. However, the time required to respond to the investigation and to disclose its findings has ultimately caused significant concern among our stakeholders, including investors. We take seriously the findings pointed out in the investigation report regarding deficiencies in our internal systems, and we are committed to making necessary improvements.
- (3) Prior to the launch of the Committee's investigation, the Company had already voluntarily reviewed its internal systems and operations and commenced efforts to standardize, systematize, and document procedures—including recordkeeping—to further enhance care quality. These efforts have also been integrated into training and are currently being implemented. We will strengthen these efforts in light of the Committee's findings.
- (4) Through organizational restructuring and optimization of staffing assignments, the Company is working to establish a framework that minimizes the likelihood of recordkeeping deficiencies. In response to the occurrence of minor discrepancies, we are committed to further strengthening our organizational structure to reduce the risk of such errors.
- (5) Further details of the Company's future initiatives in response to the investigation findings will be disclosed at the earnings announcement scheduled for August 14, 2025. We sincerely apologize once again for the great concern and inconvenience caused to all stakeholders.

5. Submission of the Semiannual Securities Report and the Second Quarter (Interim) Earnings Report for the Fiscal Year Ending September 2025

As announced in the release titled "Notice of Approval of our Application for a Deadline Extension for our Semiannual Report for the Fiscal Year Ending September 2025" dated May 15, 2025, the Company has obtained approval to extend the submission deadline to August 14, 2025. We plan to submit the semiannual securities report by that date.

In addition, as stated in the release titled "Notice on the Postponement of Financial Results Announcement for the First Six Months of the Fiscal Year Ending September 30, 2025" dated May 9, 2025, the Company plans to disclose the postponed earnings report for the second quarter (interim period) of the fiscal year ending September 2025 on August 14, 2025, concurrently with the submission of the semiannual securities report.